Kyowa Hakko Kirin Co., Limited

Kyowa Kirin Co., Ltd.

Ntt Docomo, Inc.

Nichiha Corp.

Yuji Yamazaki

Takashi Shimada

Takeyoshi Yamashita

Hitoshi Yoshida

Itaru Urakawa

Yukiko Aono

Hisashi Hasegawa

Shinya Ogawa

Kaname Kimura

David Foster Mills

Tsuguo Kubota

Yoshinori Hibino

Kiyoshi Shimizu

Tsuyoshi Yamada

Rachel Soloff Nugent

Andrew John McKnight

Naoto Miyajima

Akiko Hariguchi

Tomoko Ishii

Tomoya Murao

Masaya Higuchi

Aihua Song

John Lorca Laudenslager

Giuseppe Destito

Sarah Sunrise Bubeck

Yuko Ube

Aruna Bitra

Dirk Michael Zajonc

An antibody or antigen binding fragment thereof that binds to a Fn14, wherein the antibody or antigen binding fragment thereof is an antagonist and non-agonist of Fn14.

FN14 antibodies and uses thereof

The present invention relates to an antibody specifically binding to human growth arrest specific 6 (hGas6). Specifically, the present invention relates to a monoclonal antibody or an antibody fragment thereof which binds to at least one of amino acid residues at positions 314, 315, and 316 of human Gas6, a nucleic acid comprising a nucleotide sequence encoding the antibody or the antibody fragment, a transformed cell comprising a vector comprising the nucleic acid, a method for producing the antibody or the antibody fragment, a reagent for detection or assay of Gas6, comprising the antibody or the antibody fragment, a therapeutic agent or a diagnostic agent for a Gas6-related disease, comprising the antibody or the antibody fragment as an active ingredient, and use of the antibody or the antibody fragment for the production of a therapeutic agent or a diagnostic agent for a Gas6-related disease.

Anti human Gas6 monoclonal antibody

To provide an antibody against FGF23 and a pharmaceutical composition such as a preventive or therapeutic agent which can prevent or treat by suppressing an action of FGF23 by using the antibody. An antibody or its functional fragment against human FGF23 produced by hybridoma C10 (Accession No. FERM BP-10772).

Anti FGF23 antibody and a pharmaceutical composition comprising the same

The present invention provides an anti-BMP9 (Bone morphogenetic protein-9) monoclonal antibody or an antibody fragment thereof binding to human BMP9, a hybridoma producing the antibody or the antibody fragment, a DNA encoding the antibody or the antibody fragment, a vector comprising the DNA, a transformant obtained by introduction of the vector, a method for preparing the antibody or the antibody fragment using the hybridoma or the transformant, and a therapeutic agent comprising the antibody or the antibody fragment as an active ingredient. Further, the present invention provides a pharmaceutical composition comprising the antibody or the antibody fragment as an active ingredient for the treatment of anemia such as renal anemia, cancer anemia or the like, and a method for treating anemia such as renal anemia, cancer anemia or the like using the same.

Pharmaceutical agent comprising anti-BMP9 antibody as active ingredient for treatment of anemia such as renal anemia and cancer anemia

In a mobile communication network system for locking an operation on a cellular telephone comprised of a cellular telephone body, and an information storage medium that is inserted in the cellular telephone body and that is assigned a specific telephone number, provided are a service control apparatus that associates a terminal identification number assigned to the cellular telephone with the telephone number of the information storage medium currently inserted in the cellular telephone to manage, and an information management server which acquires a telephone number of the information storage medium corresponding to the terminal identification number of the cellular telephone targeted for locking from the service control apparatus, and locks the operation on the cellular telephone based on the telephone number.

Mobile communication network system and locking method of a mobile terminal apparatus

Provided is a high manufacturing method of the production efficiency for a wood cement board that has a pattern of recesses and projections. The method for making a wood cement board having a pattern of recesses and projections on its surface, comprising: dispersing a raw material mixture onto a template provided with recesses corresponding to the portions of the wood cement board on which projections are formed, while conveying the template, thereby forming a mat; pressurizing only a section of the mat raw material mixture that is layered on the recesses of the template from above; leveling the surface of the partly pressurized mat; and pressing the resulting mat and the template together, followed by hardening and curing.

Production method of wood cement board

The purpose of the present invention is to provide an antibody against fibroblast growth factor 23. The antibody is obtained by immunizing an animal with a polypeptide which comprises an amino acid sequence represented by SEQ ID NO: 1, or an amino acid sequence derived from the amino acid sequence represented by SEQ ID NO: 1 by deletion, substitution, or addition of 1 or several amino acids, and has fibroblast growth factor-23 activity and activity to control phosphate metabolism or vitamin D metabolism, and is shown by the following (a), (b), or (c):

Antibody against fibroblast growth factor-23

Growing community of inventors

Gunma, Japan

Yuji Yamazaki